4 Marijuana Penny Stocks Making the Right Moves


Follow this company

Companies Mentioned

PK:GWPFR / OTC:BB:MCIG / OTC:BB:TRTC / OTC:BB:NVLX
01/31/2014 [ACCESSWIRE]

The current frenzy over the potential of the legal-marijuana market is spawning cannabis penny stocks by the dozens.

The problem for potential investors is separating the wannabes from the real players. One simple formula that makes sense is to examine the basic product or service offerings of these new companies and then look for signs they are taking concrete steps to transform their hype into real action.

Here are four penny stocks in the cannabis-related industry that are making some of the right moves.

Has Approved Product

GW Pharmaceuticals plc (OTCPINK: GWPFR) share volume soared Jan. 30, with 95,647 shares changing hands, more than triple its three-month average of 29,408 shares.

This is not surprising, considering the UK-based developer of cannabis-based medicines already has one of its major products approved.

Founded in 1998, GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries.

Impressive Portfolio of Cannabis-based Medications in Pipeline

 Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world.

GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet syndrome, a severe infantile-onset, genetic, drug-resistant epilepsy syndrome. Our product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia.

On Jan. 30, GWPFR’s share price closed at $4.56, up 34 cents from its close of $4.22 the previous day.

Find out what could be the best investor’s move when it comes to GWPFR by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com/

Already Taking Orders for Low-Cost Vaporizer

mC,ig, Inc. (OTCQB: MCIG) is an Australian vaporizer manufacturer that is making an aggressive foray into the legal marijuana market.

One the ways mCig is making its play is by recently introducing an herb vaporizer that only retails for $10. On Jan. 10, the company announced that it expected to fulfill all incoming orders within 5-t-10 business days with order lead time declining to 3-to-5 business days by January 21, 2014.

“Today marks an important milestone for our company. In less than six months we have transitioned from a development stage company to launching two iterations of a device that is quickly cementing itself as the most efficient and affordable way to vaporize plant material,” stated mCig, Inc. CEO Paul Rosenberg said, in a written statement.

Strategic Acquisition

On Jan. 24, mCig announced that it acquired Vapolution, Inc., an herbal vaporizer company based in Northern California in a non-dilutive transaction that consolidates an industry leader with over $1.3 million (unaudited aggregate revenue since 2010) in sales. The company contends that the acquisition transforms mCig, Inc. into a formidable competitor in two high growth categories: Personal Vaporizers (mCig 2.0, Vapolution PocketVape) and traditional home-use Vaporizers (Vapolution 2.0).

On Jan. 30, MCIG’s share price closed at 31cents, up 1 cent from its close of 30 cents the previous day.

Find out what could be the best investor’s move when it comes to GWPFR by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com/

Taking Steps toward Licensing

Irvine, Calif.-based Terra Tech Corp. (OTCQB: TRTC), a company that provides hydroponic equipment for legal-marijuana growers, is moving aggressively into the cannabis market by applying for a permit.

On Jan. 29, Terra Tech Corp (through their subsidiary GrowOp Technology, said it formed a team focused on competing for permits to operate cannabis businesses within the state of Nevada. The team is to be headed by former principal lobbyist for the ACLU at the Nevada state legislature Rebecca Gasca, according to the release.

Hires Heavy-Duty Lobbyist

Gasca is CEO of Pistil and Stigma, a values-driven community and government relations firm that focuses on legislative change, public policy, program development, fundraising, advocacy and public relations. She is former Rotary International Goodwill Ambassador to Chile and recently served as a U.S. State Dept. Legislative Fellow to Nepal. In Nevada, she has lobbied successfully on hundreds of pieces of legislation and her firm worked closely on the medical marijuana dispensary legislation that was signed in to law by Republican Governor Brian Sandoval.

“We aligned ourselves with Rebecca due to her history of expertise in helping shape socially responsible legislation," Terra Tech Corp CEO Derek Peterson, said in a written statement.  "She has been on the ground floor in Nevada since the inception of their medical cannabis dispensary bill and was instrumental in its formation. She is heading our team and assisting us in the formation of our applications,” he added.

On Jan. 30, TRTC’s share price closed at 46 cents, up 1 cent from its close of 45 cents the previous day.

Find out what could be the best investor’s move when it comes to TRTC by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com/

Ramping Up Its Staff with Top-Notch Researchers

Nuvilex, Inc. (OTCQB: NVLX), a Silver Spring, Md. biotech company optimizing the anticancer effectiveness of cannabinoids against cancers, is an interesting player in the medical-marijuana sector.        

Over the last year it has issued a plethora of press releases about how it is positioning itself and recruiting and hiring the top researchers in the medical-marijuana field. But so far, the company has not produced any concrete products or services for the industry. Neville’s cannabis business appears to still be in the developmental stage. Still, it has hired the brain power that eventually could make it a real player.

On Jan. 30, NVLX’s share price closed at 0.181 cents, up 0.014 cents from its close of 0.167 cents the previous day.

Find out what could be the best investor’s move when it comes to NVLX by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com/ 

ABOUT US: 

Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.

Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://http://www.sixfigurestockpicks.com/

Disclosure

Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.

  
COMMENTS

Leave a comment...
 * 

Your Name
 *